Related Experiment Video
Updated: Jan 5, 2026
07:39
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
4.0K
Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction
David M Kaye1, Shane Nanayakkara1
1Heart Failure Research Group, Department of Cardiology, Baker Heart and Diabetes Institute, Alfred Hospital, Melbourne, VIC, Australia.
Frontiers in Cardiovascular Medicine
|October 18, 2019
Summary
Heart failure with preserved ejection fraction (HFpEF) lacks effective treatments. This review discusses the interatrial shunt device (IASD), a potential new therapy for HFpEF by addressing elevated left atrial pressure.
Area of Science:
- Cardiology
- Medical Devices
- Heart Failure Research
Background:
- Heart failure with preserved ejection fraction (HFpEF) constitutes a significant and growing portion of heart failure cases.
- Unlike heart failure with reduced ejection fraction (HFrEF), HFpEF currently lacks evidence-based therapeutic options.
- Key pathophysiology involves elevated left atrial pressure due to impaired left ventricular diastolic function and increased atrial stiffness.
Purpose of the Study:
- To review the clinical development of a novel device-based therapy for HFpEF.
- To explore the potential of the interatrial shunt device (IASD) as a treatment for HFpEF.
Main Methods:
- Review of clinical development data for the interatrial shunt device (IASD).
- Focus on the device's mechanism targeting elevated left atrial pressure in HFpEF.
Main Results:
- The interatrial shunt device (IASD) is presented as a potential therapeutic approach.
- The device aims to alleviate symptoms by managing left atrial pressure during physical activity.
Conclusions:
- The interatrial shunt device (IASD) represents a promising, novel device-based therapy for HFpEF.
- Further clinical development is crucial to establish the efficacy and safety of IASD for HFpEF patients.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
223
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
223
01:29Heart Failure II: Pathophysiology
651
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
651
01:29Cardiomyopathy V: Interprofessional Care
296
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
296
01:30Heart Failure IV: Classification and Diagnostic Evaluation
277
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
277
01:30Cardiomyopathy II: Dilated Cardiomyopathy
420
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
420
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K